Abstract 2751
Background
Gastrointestinal stromal tumors (GISTs) are rare mesenchymal tumors of the gastrointestinal (GI) tract. The size, the presence of a c-KIT gene mutation and the mitotic index are used to determine the prognosis and to direct systemic treatment choices. This study evaluated the use of radiomics, a technique which uses algorithms for diagnosing and predicting the c-KIT mutational status and mitotic index of GISTs from medical imaging features.
Methods
A combination of machine learning methods was used to distinguish treatment-naive GISTs from other GI tumors resembling GISTs on imaging, based on clinical and molecular characteristics, as well as imaging features extracted from the contrast-enhanced venous phase computed tomography scans. Evaluation was performed in a 100x random-split cross-validation with 20% of the data for testing.
Results
A total of 242 tumors were used for distinguishing GISTs (n = 123) from non-GISTs (n = 119) including leiomyoma (n = 25), schwannoma (n = 21), gastric carcinoma (n = 25), lymphoma (n = 23) and leiomyosarcoma (n = 25).The non-GISTs were located either gastric (23%) or non-gastric (77%) and the GISTs were located either gastric (63%) or non-gastric (37%). A c-KIT mutation was present in the majority of the GISTs (exon 9 n = 10, exon 11 n = 56, exon 13 n = 2). The dataset originated from 65 different scanners, leading to heterogeneity in the imaging protocols. Imaging feature analyses showed a mean area under the curve (mAUC) of 0.70 (95% confidence interval [CI] 0.63-0.76) for distinguishing GIST from non-GISTs. A mAUC of 0.52 (95% CI 0.32-0.72) was found for predicting all c-KIT mutations, a mAUC of 0.51 (95% CI 0.29-0.72) for predicting a c-KIT exon 9 mutation, and a mAUC of 0.61 (95% CI 0.47-0.74) for predicting a c-KIT exon 11 mutation. The mitotic index was available in 83 patients (≤5/50 high power fields (HPFs) n = 53, 43.1%, >5/50 HPFs n = 33, 26.8%), and showed a mAUC of 0.60 (95% CI 0.47-0.73).
Conclusions
This pilot study showed the potential of radiomics to distinguish GIST from other GI tumors, but no potential in predicting c-KIT mutational status and mitotic index of GISTs. Further optimization and validation of the radiomics model is required to incorporate radiomics in the diagnostic routine of GISTs.
Clinical trial identification
Editorial acknowledgement
M.J. Timbergen and M.P.A. Starmans contributed equally to this study.
Legal entity responsible for the study
The authors.
Funding
The Netherlands Organization for Scientific Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4228 - Clinical Evaluation of Drug-Eluting Bead Transcatheter Arterial Chemoembolization(D-TACE) versus Conventional TACE in Treatment of unresectable Hepatocellular Carcinoma
Presenter: Yi Chen
Session: Poster Display session 1
Resources:
Abstract
3930 - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data
Presenter: Thomas Decaens
Session: Poster Display session 1
Resources:
Abstract
5373 - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
5455 - Bioavailability of tepotinib: impact of omeprazole and food
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
2618 - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2563 - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2021 - The Addition of Metformin to Systemic Anticancer Therapy
Presenter: Jung Han Kim
Session: Poster Display session 1
Resources:
Abstract
5243 - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
Presenter: Antoine Italiano
Session: Poster Display session 1
Resources:
Abstract
598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.
Presenter: Maria Kleniewska-Wieczor
Session: Poster Display session 1
Resources:
Abstract
5381 - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study
Presenter: Ruben Van Eerden
Session: Poster Display session 1
Resources:
Abstract